Clinical Trials Logo

Mycosis Fungoides (MF) clinical trials

View clinical trials related to Mycosis Fungoides (MF).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01579318 Terminated - Clinical trials for Mycosis Fungoides (MF)

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma

CTCL
Start date: June 8, 2012
Phase: Phase 2
Study type: Interventional

A single arm, open label, multi-center, phase 2 study to assess the safety and anti-tumor activity of ImmunoPulse IL-12® in participants with stage IB to IIIB mycosis fungoides. ImmunPulseIL12® is the combination of intrtumoral interleukin-12 gene (also known as tavokinogene telseplasmid [tavo]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid [DNA] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). All participants may receive up to four cycles of treatment consisting of three treatment days, Days 1, 5 and 8, in a 12-week cycle as per Protocol version 6 (see Limitations and Caveats section of this record for protocol version information). Patients will receive intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.